190 related articles for article (PubMed ID: 22126567)
41. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
42. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
Wils J; Coombes RC; Marty M; Bliss J; Woods E
Drugs; 1993; 45 Suppl 2():46-50; discussion 49-50. PubMed ID: 7693422
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil.
Li JJ; Di GH; Tang LC; Yu KD; Hu Z; Liu GY; Lu JS; Wu J; Han QX; Shen ZZ; Shao ZM
Breast J; 2011; 17(6):657-60. PubMed ID: 21933300
[TBL] [Abstract][Full Text] [Related]
44. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier MJ; Luporsi E;
Ann Oncol; 2006 Jan; 17(1):85-92. PubMed ID: 16251204
[TBL] [Abstract][Full Text] [Related]
45. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
46. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot JY; Fargeot P; Olivier JP; Fizames C
J Clin Oncol; 1995 Jul; 13(7):1564-71. PubMed ID: 7541448
[TBL] [Abstract][Full Text] [Related]
47. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
48. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
[TBL] [Abstract][Full Text] [Related]
49. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
50. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
51. [Equalization of spread of breast cancer chemotherapy regimen at general hospitals--with EC and FEC regimens].
Kitada N; Nakayama T; Morita S; Sasaoka H; Yamasaki H; Anami S; Tatsuta M; Furukawa H; Morimoto S; Miyabe T; Hasegawa K; Tabuse K; Takara K; Yokoyama T; Watari M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):267-71. PubMed ID: 18281763
[TBL] [Abstract][Full Text] [Related]
52. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Campone M; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier MJ; Fumoleau P
Ann Oncol; 2005 Aug; 16(8):1343-51. PubMed ID: 15905306
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
54. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
[TBL] [Abstract][Full Text] [Related]
55. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.
Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
Acta Oncol; 1992; 31(2):231-6. PubMed ID: 1622639
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
Norum J; Holtmon M
Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
[TBL] [Abstract][Full Text] [Related]
57. A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Delbaldo C; Serin D; Mousseau M; Greget S; Audhuy B; Priou F; Berdah JF; Teissier E; Laplaige P; Zelek L; Quinaux E; Buyse M; Piedbois P;
Eur J Cancer; 2014 Jan; 50(1):23-30. PubMed ID: 24183460
[TBL] [Abstract][Full Text] [Related]
58. [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Darut-Jouve A; Coudert B; Jolimoy G; Belichard C; Arnoud L; Guerrin J
Bull Cancer; 1999 Feb; 86(2):189-94. PubMed ID: 10066950
[TBL] [Abstract][Full Text] [Related]
59. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Kluger N; Jacot W; Frouin E; Rigau V; Poujol S; Dereure O; Guillot B; Romieu G; Bessis D
Ann Oncol; 2012 Nov; 23(11):2879-2884. PubMed ID: 22571858
[TBL] [Abstract][Full Text] [Related]
60. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
